“I think discussing it and talking about the different techniques out there [is important],” says Svetlana Avulova, MD.
In this video, Svetlana Avulova, MD, discusses how clinicians can minimize the adverse events associated with radical cystectomy. Avulova is an assistant professor of surgery in urologic oncology at the Albany Medical Center in Albany, New York.
Cell therapy TARA-002 shows initial promise in NMIBC
April 9th 2024"This encouraging anti-tumor activity coupled with a favorable safety profile and mode of administration that is both convenient and familiar to urologists indicates that, if confirmed in future studies, TARA-002 could potentially play a meaningful role in NMIBC treatment in the future," says Timothy D. Lyon, MD.
Nadofaragene firadenovec shows durable efficacy in NMIBC
April 8th 2024"In this follow-up analysis of the phase 3 study, we demonstrated a sustained response to Adstiladrin treatment over 3 years, allowing more than half of the patients in the study to remain cystectomy free for at least 36 months,” says Colin P.N. Dinney, MD.